ArticleRSC medicinal chemistry2020
Chromone and donepezil hybrids as new multipotent cholinesterase and monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease.
Article in RSC medicinal chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- A quarter-century journey into 4-chromone derivatives: synthesis, reactions, and pioneering applications thereof.RSC advances · 2026Review
- Design, Synthesis and Biological Evaluation of Chromeno[3,4-ACS chemical neuroscience · 2025Article
- Multi-Target Drug Design in Alzheimer's Disease Treatment: Emerging Technologies, Advantages, Challenges, and Limitations.Pharmacology research & perspectives · 2025Review
- Dual Inhibitors of Acetylcholinesterase and Monoamine Oxidase-B for the Treatment of Alzheimer's Disease.Molecules (Basel, Switzerland) · 2025Review
- Inhibition of monoamine oxidases and neuroprotective effects: chalcones vs. chromones.Molecular diversity · 2025Article
- Novel Emerging Targets Identification in Reducing Risk of Alzheimer's Disease.Central nervous system agents in medicinal chemistry · 2025Review
- Recent Advances in the Search for Effective Anti-Alzheimer's Drugs.International journal of molecular sciences · 2024Review
- Article
- Synthesis of Chroman-2,4-diones via Ring-Opening/Ring-Closing Reaction Involving Palladium-Catalyzed Intramolecular Aryloxycarbonylation.The Journal of organic chemistry · 2024Article
- Latest advances in dual inhibitors of acetylcholinesterase and monoamine oxidase B against Alzheimer's disease.Journal of enzyme inhibition and medicinal chemistry · 2023Review
- A Concise Review of the Recent Structural Explorations of Chromones as MAO-B Inhibitors: Update from 2017 to 2023.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Structure-Based Design of Novel MAO-B Inhibitors: A Review.Molecules (Basel, Switzerland) · 2023Review
- Design, synthesis, and evaluation of novelJournal of enzyme inhibition and medicinal chemistry · 2022Article
- The Chemotype of Chromanones as a Privileged Scaffold for Multineurotarget Anti-Alzheimer Agents.ACS pharmacology & translational science · 2022Article
- Recent advancements in chromone as a privileged scaffold towards the development of small molecules for neurodegenerative therapeutics.RSC medicinal chemistry · 2022Review
- An overview on the synthesis of carbohydrate-based molecules with biological activity related to neurodegenerative diseases.RSC medicinal chemistry · 2021Review
- Dual acting oximes designed for therapeutic decontamination of reactive organophosphatesRSC medicinal chemistry · 2021Article
- The recent development of donepezil structure-based hybrids as potential multifunctional anti-Alzheimer's agents: highlights from 2010 to 2020.RSC advances · 2021Review
- GC-MS Metabolic Profile and α-Glucosidase-, α-Amylase-, Lipase-, and Acetylcholinesterase-Inhibitory Activities of Eight Peach Varieties.Molecules (Basel, Switzerland) · 2021Article
- From Hybrids to New Scaffolds: The Latest Medicinal Chemistry Goals in Multi-target Directed Ligands for Alzheimer's Disease.Current neuropharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A series of chromone and donepezil hybrids were designed, synthesized, and evaluated as multipotent cholinesterase (ChE) and monoamine oxidase (MAO) inhibitors for the potential therapy of Alzheimer's disease (AD).
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.